PMID- 34690930 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20221207 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 12 DP - 2021 TI - Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. PG - 731974 LID - 10.3389/fendo.2021.731974 [doi] LID - 731974 AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a worldwide epidemic. It spreads very fast and hits people of all ages, especially patients with underlying diseases such as diabetes. In this review, we focus on the influences of diabetes on the outcome of SARS-CoV-2 infection and the involved mechanisms including lung dysfunction, immune disorder, abnormal expression of angiotensin-converting enzyme 2 (ACE2), overactivation of mechanistic target of rapamycin (mTOR) signaling pathway, and increased furin level. On the other hand, SARS-CoV-2 may trigger the development of diabetes. It causes the damage of pancreatic beta cells, which is probably mediated by ACE2 protein in the islets. Furthermore, SARS-CoV-2 may aggravate insulin resistance through attacking other metabolic organs. Of note, certain anti-diabetic drugs (OADs), such as peroxisome proliferator-activated receptor gamma (PPARgamma) activator and glucagon-like peptide 1 receptor (GLP-1R) agonist, have been shown to upregulate ACE2 in animal models, which may increase the risk of SARS-CoV-2 infection. However, Metformin, as a first-line medicine for the treatment of type 2 diabetes mellitus (T2DM), may be a potential drug benefiting diabetic patients with SARS-CoV-2 infection, probably via a suppression of mTOR signaling together with its anti-inflammatory and anti-fibrosis function in lung. Remarkably, another kind of OADs, dipeptidyl Peptidase 4 (DPP4) inhibitor, may also exert beneficial effects in this respect, probably via a prevention of SARS-CoV-2 binding to cells. Thus, it is of significant to identify appropriate OADs for the treatment of diabetes in the context of SARS-CoV-2 infections. CI - Copyright (c) 2021 Shao, Yang, Pan, Yu and Chen. FAU - Shao, Shiying AU - Shao S AD - Division of Endocrinology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Branch of National Clinical Research Center for Metabolic Diseases, Hubei, China. FAU - Yang, Qin AU - Yang Q AD - Division of Pathology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Pan, Ruping AU - Pan R AD - Department of Nuclear Medicine, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. FAU - Yu, Xuefeng AU - Yu X AD - Division of Endocrinology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Branch of National Clinical Research Center for Metabolic Diseases, Hubei, China. FAU - Chen, Yong AU - Chen Y AD - Division of Endocrinology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. AD - Branch of National Clinical Research Center for Metabolic Diseases, Hubei, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211006 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 0 (Antiviral Agents) RN - 0 (Dipeptidyl-Peptidase IV Inhibitors) RN - 0 (Hypoglycemic Agents) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 3.4.17.23 (ACE2 protein, human) RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) SB - IM MH - Angiotensin-Converting Enzyme 2/antagonists & inhibitors/metabolism MH - Animals MH - Antiviral Agents/pharmacology/therapeutic use MH - COVID-19/*epidemiology/*metabolism MH - Diabetes Mellitus, Type 2/drug therapy/*epidemiology/*metabolism MH - Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use MH - Humans MH - Hypoglycemic Agents/pharmacology/therapeutic use MH - Lung/drug effects/metabolism MH - T-Lymphocytes/drug effects/metabolism MH - TOR Serine-Threonine Kinases/antagonists & inhibitors/metabolism MH - COVID-19 Drug Treatment PMC - PMC8527093 OTO - NOTNLM OT - COVID - 19 OT - OADs OT - SARS-CoV-2 (2019-nCoV) OT - diabetes - quality of life OT - immunocellular response COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/10/26 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/10/06 CRDT- 2021/10/25 06:24 PHST- 2021/06/29 00:00 [received] PHST- 2021/09/17 00:00 [accepted] PHST- 2021/10/25 06:24 [entrez] PHST- 2021/10/26 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/10/06 00:00 [pmc-release] AID - 10.3389/fendo.2021.731974 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2021 Oct 6;12:731974. doi: 10.3389/fendo.2021.731974. eCollection 2021.